Treatment-emergent AEs (TEAEs) are shown in Table 5. Six participants reported 10 TEAEs, 5 of which were treatment-related in 5 participants (two events of epistaxis, two events of headache, and one event of sinusitis). No new significant safety information was identified from these AEs. There were no severe TEAEs, and no participants withdrew from the study due to AEs. Participants who reported using the product more than three times a day did not report any safety issues.